An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD) (NCT06996652)
🩺 Plain-English Summary (8th-Grade Level)
This is a phase 2 study to assess the ability of adalimumab as compared to placebo to reduce or prevent progression of synuclein-related neurodegeneration in persons with idiopathic REM Sleep Behavior Disorder (RBD). The Primary Endpoint will be change from baseline in expression of the Parkinson Disease Related Pattern (PDRP) will be assessed using change in 18-flurodeoxyglucose (FDG) Positron Emission Tomography (PET) imaging.
Who can join: Review the eligibility criteria below.
Location: Cedars Sinai Medical Center — Los Angeles, California
Age range: 50 Years to 80 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (19 Sites)
- Cedars Sinai Medical Center — Los Angeles, California
- University of Colorado Anschutz — Aurora, Colorado
- Yale Medicine — North Haven, Connecticut
- Parkinson's Disease & Movement Disorders Center of Boca Raton — Boca Raton, Florida
- Emory University School of Medicine — Atlanta, Georgia
- Johns Hopkins University — Baltimore, Maryland
- Massachusetts General Hospital — Boston, Massachusetts
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- University of Minnesota — Minneapolis, Minnesota
- Washington University — St Louis, Missouri
- Cleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas — Las Vegas, Nevada
- Dartmouth Hitchcock Medical Center — Lebanon, New Hampshire
- Weill Medical College of Cornell University — New York, New York
- Oregon Health & Science University — Portland, Oregon
- University of Pennsylvania — Philadelphia, Pennsylvania
- Medical University of South Carolina — Charleston, South Carolina
- University of Texas Houston Medical Center — Houston, Texas
- University of Texas Health Science Center- San Antonio — San Antonio, Texas
- Montreal Neurological Institute-Hospital at McGill University — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (475) 254-9169
Email: erika.renkl@yale.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in REM Sleep Behavior Disorder
- Terazosin Effect on Cardiac Changes in Early Parkinson's Disease — Los Angeles, California
- Adrenergic Blockers for Cardiac Changes in Early Parkinson's Disease (Protocol 53136) — Los Angeles, California
- Cardiac Changes in Early Parkinson's Disease: A Follow up Study — Los Angeles, California
- Neuroplasticity in RBD — Minneapolis, Minnesota
Explore by condition: All REM Sleep Behavior Disorder clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.